# Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation

Study · id `cardio:ct-nct01140581` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01140581](<https://clinicaltrials.gov/study/NCT01140581>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01140581

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

## Technical summary

Registry record NCT01140581. Randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 402 participants (enrolled count; ClinicalTrials.gov record NCT01140581, source copy `cardio:ctgov-nct01140581-2012-01-23`, retrieved 2026-10-26)
- Start date: 2010-09 (registry gives no type) (ClinicalTrials.gov record NCT01140581, source copy `cardio:ctgov-nct01140581-2012-01-23`, retrieved 2026-10-26)
- Primary completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01140581, source copy `cardio:ctgov-nct01140581-2012-01-23`, retrieved 2026-10-26)
- Completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01140581, source copy `cardio:ctgov-nct01140581-2012-01-23`, retrieved 2026-10-26)
- Countries: Australia; Austria; Estonia; Finland; France; Germany; Israel; Italy; Mexico; Netherlands; Portugal; South Korea; Spain; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT01140581, source copy `cardio:ctgov-nct01140581-2012-01-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01140581-2012-01-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
- Acronym: ARTEMIS Load
- Condition: Atrial Fibrillation
- Intervention (Drug): DRONEDARONE
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 0a78965d9707770e938cc12907bbffad8991d104c7e2b7c7eda891a06e6e1643
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
